抗肿瘤抗生素抗体靶向药物研究新进展

摘要/Abstract

摘要： 新近研究发现,卡里奇霉素、力达霉素等抗肿瘤抗生素对某些靶点显示高度活性,对癌细胞具有极强的杀伤作用,可以作为高效“弹头”药物,用于构建抗体靶向药物,包括化学免疫偶联物和融合蛋白。抗体靶向药物由于体内分布的特异性及作用的专一性,具有强大的抗肿瘤优势。本文主要对几类抗肿瘤抗生素抗体靶向药物的构建及作用特点等进行综述,并初步展望其未来研究方向。

关键词: 抗肿瘤抗生素, 抗体靶向药物, 免疫偶合物, 强化融合蛋白

Abstract: Recent studies have reported that some antibiotics such as calicheamicin and lidamycin display potent cytotoxicity respectively to variousmolecular targets, so they can be used as potent “warhead” agent to constitute antibody-targeted conjugates including immunoconjugates and fusion proteins. Antibody-targeted drugs exert a powerful antitumor potency because of its specific distribution and function in vivo. This paper mainly reviews on the construction and effect characteristics of antibody-targeted conjugates of antitumor antibiotics and provide a preliminary outlook for its future research direction.

Key words: antitumor antibiotics, antibody-targeted conjugates, immunoconjugate, energized fusion proteins

中图分类号:

R963

尚利娜, 洪明岳. 抗肿瘤抗生素抗体靶向药物研究新进展[J]. 中国临床药理学与治疗学, 2014, 19(9): 1075-1080.

SHANG Li-na, HONG Ming-yue. Recent progresses on antibody-targeted conjugates of antitumor antibiotics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1075-1080.

参考文献 34

[1]	Verdoodt B, Vogt M, Schmitz I, et al.Salinomycin induces autophagy in colon and breastcancer cells with concomitant generation of reactive oxygen species[J].PLo S One,2012,7(9): e44132.
[2]	Li W, Khullar A, Chou S, et al.Biosynthesis of Sibiromycin, a Potent Antitumor Antibiotic[J]. Appl Environ Microbiol,2009,75(9):2869-2878.
[3]	Flygare JA, Pillow TH, Aristoff P.Antibody-drug conjugates for the treatment of cancer[J]. Chemical Biology & Drug Design,2013,81(1):113-121.
[4]	钱璟. 烯二炔类抗肿瘤抗生素的研究进展[J].中国现代药物应用,2012,6(22):124-125.
[5]	Feng Y, Shao RG, Dai Y, et al.Comparison of the antitumor activities of immuneconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers[J].Yao Xue Xue Bao,2010,45(5):571-575.
[6]	Fang H, Miao Q.Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin[J].Sci China Life Sci,2011,54(3):255-262.
[7]	Zhong GS, Wu MN, Guo XF, et al.Small antibody fusion proteins with complementarity -determining regions and lidamycin for tumor targeting therapy[J].Oncol Lett,2013,5(4): 1183-1188.
[8]	高瑞娟,李亮,赵春燕,等.单链抗体与力达霉素基因工程强化融合蛋白Fv-LDP-AE 的抗肿瘤作用[J].中国药学杂志,2010,58(11):808-813.
[9]	Zhang Q, Liu XJ, Hu L, et al.Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy[J].Int J Mol Med,2012,29(3): 409-415.
[10]	Zhang Q, Liu XJ, Li C, et al.Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma[J].Oncol Lett,2013,6(3): 801-806.
[11]	郭晓芳,来小飞,钟根深,等.以人表皮生长因子受体 2 为靶点的强化融合蛋白 LDP-Hr-AE 的构建及抗肿瘤活性研究[J].中国药学杂志,2012,47(12):941-947.
[12]	Ricart AD.Antibody-drug conjugates of calicheamicin derivative: gemtuzumabozogamicin and inotuzumabozogamicin[J].Clin Cancer Res,2011,17(20): 6417-6427.
[13]	de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumabozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells[J].Leukemia,2012,26(2):255-264.
[14]	DiJoseph JF, Dougher MM, Evans DY, et al. Preclinical anti-tumor activity of antibody-targetedchemotherapy with CMC-544 (inotuzumabozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemo- therapy with CVP or CHOP[J].Cancer Chemother Pharmacol,2011,67(4):741-749.
[15]	Ogura M, Hatake K, Ando K, et al.Phase I study of anti-CD22 immunoconjugate inotuzumabozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma[J].Cancer Sci,2012,103(5): 933-938.
[16]	Shao RG.Pharmacology and therapeutic applications of enediyne antitumor antibiotics[J]. Curr Mol Pharmacol,2008,1(1): 50-60.
[17]	Bernt KM, Prokop A, Huebener N, et al.Eradication of CD19+ leukemia by targeted calicheamicin theta[J].Bioconjug Chem,2009,20(8): 1587-1594.
[18]	Nagamitsu A, Greish K, Maeda H.Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors[J].Jpn J Clin Oncol,2009,39(11):756-766.
[19]	YataY, Otsuji E, Okamoto K, et al. Decreased production of anti-mouse antibody after administration of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate to human[J].Hepatogastroenterology,2003,50(49):80-84.
[20]	Jin W, Trzupek JD, Rayl TJ, et al.A unique class of duocarmycin and CC-1065 analogues subject to reductive activation[J]. J Am Chem Soc,2007,129(49):15391-15397.
[21]	Wang Y, Jiang J, Jiang XJ, et al.Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog[J].Bioorg Med Chem,2008,16(13): 6552-6559.
[22]	Suzawa T, Nagamura S, Saito H, et al.Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation[J].Bioorg Med Chem,2000,8(8): 2175-2184.
[23]	Lillo AM, Sun C, Gao C, et al.A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents[J].Chem Biol,2004,11(7):897-906.
[24]	Sivam GP, Martin PJ, Peisfeld RA, et al.Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma[J]. Cancer Res,1995,55(11):2352-2356.
[25]	Willner D, Trail PA, Hofstead SJ, et al.(6-Maleimidocaproyl) hydrazone of doxorubicin- a new derivative for the preparation of immunoconjugates of doxorubicin[J]. Bioconjug Chem,1993,4(6):521-527.
[26]	Tan L, Neoh KG, Kang ET, et al.PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells[J].Macromol Biosci,2011,11(10): 1331-1335.
[27]	Schmid B, Chung DE, Warnecke A, et al.Albumin-binding prodrugs of camptothecin and doxorubicin with an ala-leu-ala-leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy[J].Bioconjug Chem,2007,18(3):702-716.
[28]	Jeffrey SC, Nguyen MT, Andreyka JB, et al.Dipeptide-based highly potent doxorubicin antibody conjugates[J].Bioorg Med Chem Lett,2006,16(2):358-362.
[29]	Han LA, Huang RQ, Li JF, et al.Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoaminedendrimer[J]. Biomaterials,2011,32(4): 1242-1252.
[30]	Hu ZL, Jiang XJ, Albright CF, et al.Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents[J].Bioorg Med Chem Lett,2010,20(3): 853-856.
[31]	杨鸣琦,张福良,路宏朝.抗肿瘤抗生素研究进展[J].西北农林科技大学学报,2005,23(12):27-32.
[32]	戴垚,刘秀均,甄永苏.抗 IV 型胶原酶单抗与平阳霉素新型免疫偶联物的抗肿瘤作用[J].药学学报,2006,41(1):41-46.
[33]	Chen WZ, Zhang Y, Liang CS, et al.Effect of antibody-targeted chemotherapy with pingyangmycin on prostate cancer cells in vitro[J].Nan Fang Yi Ke Da Xue Xue Bao,2008, 28(3):406-408.
[34]	L ZhD.Preparation of conjugate of chemotactic peptide fMLP-boanmycin and initial evaluation of its antitumor activity in vivo[J].China Pharmacist,2010,1:012.